Adalimumab

Avoid use with HUMIRA due to immunosuppression.

Increased risk of serious infection when combined with TNF blockers; not recommended in RA patients.

7 DRUG INTERACTIONS Abatacept: Increased risk of serious infection ( 5.1 , 5.11 , 7.2 ) Anakinra: Increased risk of serious infection ( 5.1 , 5.7 , 7.2 ) Live vaccines: Avoid use with YUFLYMA ( 5.10 , 7.3 ) 7.1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent clearance of adalimumab, the data do not suggest the need for dose adjustment of either YUFLYMA or MTX [see Clinical Pharmacology ( 12.3 )] . It is possible for products that antagonize cytokine activity, such as adalimumab products, to influence the formation of CYP450 enzymes.

7 DRUG INTERACTIONS • Abatacept: Increased risk of serious infection ( 5.1 , 5.11 , 7.2 ) • Anakinra: Increased risk of serious infection ( 5.1 , 5.7 , 7.2 ) • Live vaccines: Avoid use with Adalimumab-adaz ( 5.10 , 7.3 ) * Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of Adalimumab-adaz has been demonstrated for the condition(s) of use (e.g. 7.1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX).

( 5.1 , 5.7 , 7.2 ) Live vaccines: Avoid use with Adalimumab-adbm. ( 5.10 , 7.3 ) 7.1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent clearance of adalimumab, the data do not suggest the need for dose adjustment of either Adalimumab-adbm or MTX [see Clinical Pharmacology (12.3) ] .

7 DRUG INTERACTIONS Abatacept: Increased risk of serious infection ( 5.1 , 5.11 , 7.2 ) Anakinra: Increased risk of serious infection ( 5.1 , 5.7 , 7.2 ) Live vaccines: Avoid use with YUSIMRY ( 5.10 , 7.3 ) 7.1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either YUSIMRY or MTX [see Clinical Pharmacology ( 12.3 ) ]. It is possible for products that antagonize cytokine activity, such as adalimumab products, to influence the formation of CYP450 enzymes.

7 DRUG INTERACTIONS Abatacept: Increased risk of serious infection ( 5.1 , 5.11 , 7.2 ) Anakinra: Increased risk of serious infection ( 5.1 , 5.7 , 7.2 ) Live vaccines: Avoid use with AMJEVITA ( 5.10 , 7.3 ) 7.1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent clearance of adalimumab, the data do not suggest the need for dose adjustment of either AMJEVITA or MTX [see Clinical Pharmacology (12.3) ] . It is possible for products that antagonize cytokine activity, such as adalimumab products, to influence the formation of CYP450 enzymes.

7 DRUG INTERACTIONS • Abatacept: Increased risk of serious infection ( 5.1 , 5.11 , 7.2 ) • Anakinra: Increased risk of serious infection ( 5.1 , 5.7 , 7.2 ) • Live vaccines: Avoid use with HADLIMA ( 5.10 , 7.3 ) 7.1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HADLIMA or MTX [see Clinical Pharmacology ( 12.3 )] . It is possible for products that antagonize cytokine activity, such as adalimumab products, to influence the formation of CYP450 enzymes.

( 5.1 , 5.7 , 7.2 ) • Live vaccines: Avoid use with Adalimumab-fkjp. Biosimilarity of ADALIMUMAB-FKJP has been demonstrated for the condition(s) of use (e.g. 7.1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX).

( 5.1 , 5.7 , 7.2 ) Live vaccines: Avoid use with Adalimumab-ryvk. ( 5.10 , 7.3 ) 7.1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent clearance of adalimumab, the data do not suggest the need for dose adjustment of either Adalimumab-ryvk or MTX [see Clinical Pharmacology ( 12.3 )] .

Increased risk of serious infection when combined with TNF blockers; not recommended in RA patients.

A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocker.

Monitoring of drug concentration recommended upon initiation or discontinuation of HUMIRA; dose adjustment may be needed.

MTX reduces apparent adalimumab clearance but no dose adjustment needed for either drug.

Monitoring of drug concentration recommended upon initiation or discontinuation of HUMIRA; dose adjustment may be needed.

Monitoring of effect recommended upon initiation or discontinuation of HUMIRA; dose adjustment may be needed.

( 5.10 , 7.3 ) 7.1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either IDACIO or MTX [see Clinical Pharmacology ( 12.3 )] . It is possible for products that antagonize cytokine activity, such as adalimumab products, to influence the formation of CYP450 enzymes.

( 5.10 , 7.3 ) 7.1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent clearance of adalimumab, the data do not suggest the need for dose adjustment of either ABRILADA or MTX [see Clinical Pharmacology (12.3) ] . It is possible for products that antagonize cytokine activity, such as adalimumab products, to influence the formation of CYP450 enzymes.